Letters Section Editor: Robert M. Golub, MD, Senior Editor.
To the Editor: Dr Bongartz and colleagues1 reported the results of a meta-analysis of randomized clinical trials of the TNF-blocking monoclonal antibodies infliximab and adalimumab, finding an increased risk of serious infections and malignancies associated with their use. However, previous meta-analyses of randomized clinical trials of infliximab and adalimumab were conducted at the request of the US Food and Drug Administration (FDA), leading to revised product labeling for infliximab in September 2005 and for adalimumab in October 2005.
Okada SK, Siegel JN. Risk of Serious Infections and Malignancies With Anti-TNF Antibody Therapy in Rheumatoid Arthritis. JAMA. 2006;296(18):2201–2204. doi:10.1001/jama.296.18.2201-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: